Sierra Oncology Inc., of Vancouver, British Columbia, said it was cleared by U.K. regulators to amend the two ongoing phase I trials for Chk1 inhibitor SRA-737 to include cohort expansions of prospectively selected patients with tumors identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition.